ICM
OTLKW

Ionic Capital Management’s Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 OTLKW Stock Holding History

Ionic Capital Management’s Portfolio OTLKW Stock Details OTLKW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-17,826
Closed -$6K – 123
2019
Q1 		$6K Buy
+17,826
New +$5.72K ﹤0.01% 97

Other funds holding OTLKW

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Ionic Capital Management's OTLKW Position: Q2 2019 in Review

Ionic Capital Management sold out of Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 (OTLKW) in Q2 2019, closing a stake of 17,826 shares — an estimated $6K sold.

Ionic Capital Management first reported a position in OTLKW in Q1 2019 and held it in 1 quarter. The position peaked at $6K in Q1 2019. 7 funds tracked by Wall St. Rank hold OTLKW as of Q2 2019.

  • Ionic Capital Management reported no remaining Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 position as of Q2 2019 after selling out during the quarter.
  • Ionic Capital Management sold 17,826 Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 shares in Q2 2019, an estimated $6K.
  • Ionic Capital Management first reported a position in Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 in Q1 2019 and held it in 1 quarter.
  • Ionic Capital Management's Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 position peaked at $6K in Q1 2019.
  • 7 funds tracked by Wall St. Rank held Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 as of Q2 2019.

Based on Ionic Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.